CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (vol 12, 942341, 2022)

被引：0

作者：

Digiacomo, Graziana ^{[1
]}

Fumarola, Claudia ^{[1
]}

La Monica, Silvia ^{[1
]}

Bonelli, Mara ^{[1
]}

Cavazzoni, Andrea ^{[1
]}

Galetti, Maricla ^{[2
]}

Terenziani, Rita ^{[1
]}

Eltayeb, Kamal ^{[1
]}

Volta, Francesco ^{[1
]}

Zoppi, Silvia ^{[1
]}

Bertolini, Patrizia ^{[3
]}

Missale, Gabriele ^{[1
,4
]}

Alfieri, Roberta ^{[1
]}

Petronini, Pier Giorgio ^{[1
]}

机构：

[1] Univ Parma, Dept Med & Surg, Parma, Italy

[2] INAIL Italian WorkersCompensat Author, Dept Occupat & Environm Med Epidemiol & Hyg, Rome, Italy

[3] Univ Hosp Parma, Paediat Hematol Oncol Unit, Parma, Italy

[4] Univ Hosp Parma, Unit Infect Dis & Hepatol, Parma, Italy

来源：

关键词：

hepatocarcinoma (HCC); CDK4/6; inhibition; abemaciclib; lenvatinib; senescence;

D O I：

10.3389/fonc.2024.1532291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3